Novo Nordisk Logo

Novo Nordisk

Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.

NOVO | CO

Overview

Corporate Details

ISIN(s):
DK0062498333 (+1 more)
LEI:
549300DAQ1CVT6CXN342
Country:
Denmark
Address:
Novo Alle 1, 2880 Bagsværd
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Novo Nordisk is a global healthcare company that discovers, develops, and manufactures innovative biological medicines and therapeutic devices. With a focus on driving change to defeat serious chronic diseases, the company's primary treatment areas include diabetes, obesity, and rare blood and endocrine disorders. Leveraging over 90 years of innovation, Novo Nordisk provides pharmaceutical products and services to patients worldwide, aiming to make its treatments accessible and improve health outcomes.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Novo Nordisk and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-10 07:00
Regulatory News Service
English 11.2 KB
2025-09-10 07:00
Earnings Release
English 151.5 KB
2025-08-19 13:37
Director's Dealing
English 17.4 KB
2025-08-19 13:37
Director's Dealing
English 144.5 KB
2025-08-12 14:25
Director's Dealing
English 144.4 KB
2025-08-12 14:25
Director's Dealing
English 17.4 KB
2025-08-08 15:15
Director's Dealing
English 17.4 KB
2025-08-08 15:15
Director's Dealing
English 144.5 KB
2025-08-07 17:30
Director's Dealing
English 159.1 KB
2025-08-07 17:30
Director's Dealing
English 30.5 KB
2025-08-06 07:30
Earnings Release
English 1.4 MB
2025-08-06 07:30
Earnings Release
English 11.9 KB
2025-07-29 13:35
Board/Management Information
English 12.0 KB
2025-07-29 13:35
Board/Management Information
English 176.8 KB
2025-07-29 13:01
Earnings Release
English 167.4 KB

Automate Your Workflow. Get a real-time feed of all Novo Nordisk filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Novo Nordisk via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan 4599
STENOCARE A/S Logo
Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.
Denmark STENO
Sumitomo Pharma Co., Ltd. Logo
R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.
Japan 4506
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden SOBI
SymBio Pharmaceuticals Limited Logo
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan 4582
SynAct Pharma Logo
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
Sweden SYNACT
Synbiotic SE Logo
A vertically integrated European group for the entire hemp and cannabis value chain.
Germany SBX
Synektik S.A. Logo
Manufactures radiopharma; provides medical equipment, IT solutions, and services to specialists.
Poland SNT

Talk to a Data Expert

Have a question? We'll get back to you promptly.